Oxford BioMedica (OXBDF) Stock Price, News & Analysis

Company Overview

Oxford BioMedica plc is a UK‐based gene and cell therapy company specializing in the development and manufacture of advanced viral vector technologies. Founded as a spin-out from the University of Oxford in 1995, the company has grown into a global player in lentiviral vector research, production and commercial supply. Headquartered in Oxford, England, with a manufacturing facility in Segrate, Italy, Oxford BioMedica leverages its proprietary LentiVector® platform to advance treatments across a range of therapeutic areas.

The company’s core activities include the discovery, preclinical and clinical development of gene therapies, as well as contract development and manufacturing (CDMO) services for third-party biopharmaceutical partners. Its pipeline encompasses candidates targeting neurological disorders, oncology and ophthalmology, while its CDMO business supports high-profile collaborations such as the manufacturing of CAR-T cell therapies with Novartis and lentiviral vectors for vaccine candidates with global research organizations. Through these partnerships, Oxford BioMedica has demonstrated scalable, GMP-compliant production of clinical-grade vectors.

Over its history, Oxford BioMedica has built a robust intellectual property portfolio covering lentiviral vector design, vector production methods and gene delivery technologies. The company’s first vector was produced in the late 1990s, and since securing a London AIM listing in 2000, it has steadily expanded both its R&D footprint and manufacturing capacity. Today, its technologies serve clients and collaborators across Europe, North America and Asia, underpinning efforts to develop next-generation cell and gene therapies for rare and debilitating diseases.

Oxford BioMedica is led by CEO John Dawson, supported by an executive team with deep expertise in bioprocessing, regulatory affairs and clinical development. The board and management combine academic roots with commercial experience, guiding the company through strategic growth initiatives and the advancement of its proprietary pipeline. With a foundation in pioneering research and a focus on scalable manufacture, Oxford BioMedica continues to position itself at the forefront of the evolving gene therapy landscape.

Key Stats

• Today's Range: $4.77 to $4.77
• 50-Day Range: $3.93 to $4.77
• 52-Week Range: $3.15 to $5.68
• Volume: N/A
• Average Volume: 601 shs
• Market Capitalization: $505.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OXBDF Stock Analysis - Frequently Asked Questions

How have OXBDF shares performed this year?

Oxford BioMedica's stock was trading at $5.3950 on January 1st, 2025. Since then, OXBDF shares have decreased by 11.6% and is now trading at $4.77.

How do I buy shares of Oxford BioMedica?

Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:OXBDF
• Previous Symbol: NASDAQ:OXBDF
• CIK: N/A
• Web: www.oxfordbiomedica.co.uk
• Phone: 44-18-6578-3000
• Fax: N/A
• Employees: 891
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $111.34 million
• Price / Sales: 4.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.01 per share
• Price / Book: 4.72

Miscellaneous

• Outstanding Shares: 105,960,000
• Free Float: N/A
• Market Cap: $505.43 million
• Optionable: Not Optionable
• Beta: 1.11